Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Orsi

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
The Lancet. Gastroenterology & Hepatology|December 15, 2022
Lessons and open questions in borderline resectable pancreatic cancerMichele Reni, Giulia Orsi
The Lancet. Oncology|July 10, 2022
Pancreatic cancer: still a cold case?Michele Reni, Giulia Orsi
Hepatobiliary Surgery and Nutrition|September 7, 2019
Sorafenib and metformin: to be, or not to be, that is the questionGiulia Orsi, Andrea Casadei-Gardini
JAMA Oncology|October 6, 2022
Is the Delphi's Oracle Pertinent to Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma?Michele Reni, Marina Macchini, Giulia Orsi
Expert Review of Anticancer Therapy|January 8, 2020
Developments in predictive biomarkers for hepatocellular carcinoma therapyAndrea Casadei-Gardini, Giulia Orsi, Francesco Caputo, et al.
Lancet (London, England)|May 3, 2026
Clinical implications and biomarkers in the PACT-21 CASSANDRA trial - Authors' replyMichele Reni, Giulia Orsi, Michele Milella, et al.
Critical Reviews in Oncology/Hematology|November 19, 2018
To resect or not to resect: The hamletic dilemma of primary tumor resection in patients with asymptomatic stage IV colorectal cancerFabio Gelsomino, Andrea Spallanzani, Giulia Orsi, et al.
Expert Review of Anticancer Therapy|September 18, 2018
Lenvatinib as a therapy for unresectable hepatocellular carcinomaAndrea Spallanzani, Giulia Orsi, Kalliopi Andrikou, et al.
World Journal of Gastrointestinal Oncology|March 28, 2017
Heavily calcified gastrointestinal stromal tumors: Pathophysiology and implications of a rare clinicopathologic entityMassimiliano Salati, Giulia Orsi, Luca Reggiani Bonetti, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 16, 2023
Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinomaMichele Reni, Umberto Peretti, Marina Macchini, et al.
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
The Lancet. Gastroenterology & Hepatology|December 15, 2022
Lessons and open questions in borderline resectable pancreatic cancerMichele Reni, Giulia Orsi
The Lancet. Oncology|July 10, 2022
Pancreatic cancer: still a cold case?Michele Reni, Giulia Orsi
Hepatobiliary Surgery and Nutrition|September 7, 2019
Sorafenib and metformin: to be, or not to be, that is the questionGiulia Orsi, Andrea Casadei-Gardini
JAMA Oncology|October 6, 2022
Is the Delphi's Oracle Pertinent to Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma?Michele Reni, Marina Macchini, Giulia Orsi
Expert Review of Anticancer Therapy|January 8, 2020
Developments in predictive biomarkers for hepatocellular carcinoma therapyAndrea Casadei-Gardini, Giulia Orsi, Francesco Caputo, et al.
Lancet (London, England)|May 3, 2026
Clinical implications and biomarkers in the PACT-21 CASSANDRA trial - Authors' replyMichele Reni, Giulia Orsi, Michele Milella, et al.
Critical Reviews in Oncology/Hematology|November 19, 2018
To resect or not to resect: The hamletic dilemma of primary tumor resection in patients with asymptomatic stage IV colorectal cancerFabio Gelsomino, Andrea Spallanzani, Giulia Orsi, et al.
Expert Review of Anticancer Therapy|September 18, 2018
Lenvatinib as a therapy for unresectable hepatocellular carcinomaAndrea Spallanzani, Giulia Orsi, Kalliopi Andrikou, et al.
World Journal of Gastrointestinal Oncology|March 28, 2017
Heavily calcified gastrointestinal stromal tumors: Pathophysiology and implications of a rare clinicopathologic entityMassimiliano Salati, Giulia Orsi, Luca Reggiani Bonetti, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 16, 2023
Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinomaMichele Reni, Umberto Peretti, Marina Macchini, et al.
Pageof 6